Rooting Out Rubella: Making It Mission Possible
Express Pharma|April 01 2017

The government needs to quash fears about safety of the rubella vaccine and establish its efficacy to achieve its goal of eliminating the disease by 2020

Prathiba Raju
Rooting Out Rubella: Making It Mission Possible

The Union Health Ministry is leaving no stone unturned to eliminate and control congenital rubella syndrome (CRS) by 2020, a disease that causes birth defects such as irreversible deafness and blindness in nearly 40,000 children every year. In a bid to eradicate the rubella virus and achieve success as in the case of polio and maternal and neonatal tetanus, the health ministry has launched a concerted, nation-wide measles-rubella vaccination (MR-VAC) campaign for children aged between nine months and 15 years.

However, phase-1 of the campaign which covers Karnataka, Tamil Nadu, Goa, Puducherry and Lakshadweep has encountered a roadblock in the form of a controversy. There is a rumour going around through Whatsapp messages, SMS alerts, text and AV clips on social media forums that the vaccine is banned in the US as it causes serious side effects which include damaging a child’s immunity and memory. It is being pushed in India by the global pharma industry which is looking for a market to dump substandard products.

However, the Ministry remains undeterred in its course. Claiming that the government faces these hurdles each time a new vaccination campaign is launched, Dr Pradeep Haldar, Deputy Commissioner (Immunisation), Union Ministry of Health says, “During the polio vaccine campaign, we faced a similar kind of situation where people had a mistrust on the immunisation programme. Whenever the government has a targeted eradication campaign and tries to reach the last mile on a targeted time frame such an issue arises. But the government is well prepared to overcome these challenges. However, now they are bigger as the size of the number of children to be covered is three times more than what we did for polio programme. We are covering from children aged from nine months to 15 years.”

Diese Geschichte stammt aus der April 01 2017-Ausgabe von Express Pharma.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

Diese Geschichte stammt aus der April 01 2017-Ausgabe von Express Pharma.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

WEITERE ARTIKEL AUS EXPRESS PHARMAAlle anzeigen
Nutraceutical M&As: How strategic mergers are shaping the health and wellness market
Express Pharma

Nutraceutical M&As: How strategic mergers are shaping the health and wellness market

The nutraceutical industry has seen a surge in M&A activity over the past three years as companies pursue strategic acquisitions to strengthen market positions, diversify offerings, and drive innovation. Sudhindran N, GM - Corporate Affairs, Nutrify Today explores key trends, motivations, notable deals, and future growth prospects shaping the industry

time-read
3 Minuten  |
December 2024
Rising research costs, complex drug systems, stringent regulations, and global pressures pose major threats to pharma R&D
Express Pharma

Rising research costs, complex drug systems, stringent regulations, and global pressures pose major threats to pharma R&D

According to one of the published reports, the pharma industry invested about $83 billion in R&D in 2019, which is about 10 times the research and development (R&D) spent per year in the 1980s, after adjusting for the effects of inflation.

time-read
1 min  |
December 2024
Harnessing data analytics to propel drug discovery and development in 2025
Express Pharma

Harnessing data analytics to propel drug discovery and development in 2025

As the pharma landscape evolves, data analytics will be at the forefront of drug discovery and development, transforming traditional methods. By leveraging data-driven insights, companies can expedite R&D, optimise clinical trials, and personalise treatments, bringing life-saving therapies to market more efficiently, explains Biju Davis, SVP, Engineering, Model N

time-read
4 Minuten  |
December 2024
Strengthening our presence within APAC through increased penetration is a key focus
Express Pharma

Strengthening our presence within APAC through increased penetration is a key focus

Aanchal Tomar, Executive Director, Asia Pacific, Lonza Capsules Health Ingredients speaks about Lonza Capsules Health Ingredients’ strategic growth, challenges, and sustainability initiatives in the APAC market, showcasing their innovative capsule solutions and health ingredients that cater to the region's diverse pharmaceutical and nutraceutical needs, in an interview with Express Pharma

time-read
4 Minuten  |
December 2024
Responsible Sourcing and Manufacturing: Growing towards a sustainable future with Lonza
Express Pharma

Responsible Sourcing and Manufacturing: Growing towards a sustainable future with Lonza

In response to the establishment of environmental impact targets by the pharmaceutical industry, Lonza promotes responsible sourcing practices, sustainable manufacturing standards, and renewable energy utilisation showcasing that responsible manufacturing can assist our customers to reach their sustainability goals, highlights Christine Lebeault, Head of Applied Sustainability, Lonza Capsules and Health Ingredients

time-read
3 Minuten  |
December 2024
Rethinking R&D to balance efficiency, innovation and sustainability
Express Pharma

Rethinking R&D to balance efficiency, innovation and sustainability

In an era of skyrocketing research costs and complex drug delivery challenges, pharma industry leaders share their insights on adopting advanced technologies, data-driven decision-making, and sustainable practices to optimise R&D and drive impactful therapies to market

time-read
5 Minuten  |
December 2024
Powerful Process Control with IND500x Weighing Indicators
Express Pharma

Powerful Process Control with IND500x Weighing Indicators

Ensuring consistent quality in hazardous environments, particularly in Ex-Areas (Zone 1/21, Division 1), is a critical aspect of industrial operations. The IND500x weighing indicators from METTLER TOLEDO provide a robust solution for these challenging settings, offering optimized safety and productivity.

time-read
1 min  |
November 2024
Ensuring clean room integrity with prime clean reset high-speed doors
Express Pharma

Ensuring clean room integrity with prime clean reset high-speed doors

Prime Clean Reset high-speed doors ensure airtight seals, minimising air permeability and contamination in clean rooms. Designed for sensitive environments, they enhance operational efficiency and meet rigorous regulatory standards, making them ideal for pharmaceutical and biotech industries

time-read
3 Minuten  |
November 2024
Complete environmental monitoring solution - testo Saveris Pharma
Express Pharma

Complete environmental monitoring solution - testo Saveris Pharma

There are several critical applications in the industry like research and development that demand for continuous & reliable monitoring of important environmental parameters.

time-read
3 Minuten  |
November 2024
Adaptive Manufacturing:-The new flexibility in medical device assembly
Express Pharma

Adaptive Manufacturing:-The new flexibility in medical device assembly

Unlike traditional, rigid production lines, B&R's adaptive machines seamlessly adjust to the requirements of each device, dynamically adapting to each unique process

time-read
3 Minuten  |
November 2024